Cerus Corporation (CERS)

1,6600 -0,0200 (-1,19 %) À la clôture : 04:00PM EDT

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 625

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. William M. Greenman	President, CEO & Director	1,33M	627k	1967
Mr. Kevin D. Green	VP of Finance & CFO	748,49k	S.O.	1972
Mr. Vivek K. Jayaraman	Chief Operating Officer	861,67k	S.O.	1975
Ms. Chrystal Jensen	Chief Legal Officer & General Counsel	692,16k	S.O.	1971
Dr. Richard J. Benjamin	Chief Medical Officer	719,74k	S.O.	1960
Dr. Laurence M. Corash	Co-Founder & Chief Scientific Officer	697,77k	191,79k	1944
Ms. Lori L. Roll	VP of Administration & Corporate Secretary	S.O.	S.O.	S.O.
Mr. Matthew M. Notarianni	Senior Director of Investor Relations	S.O.	S.O.	S.O.
Lainie Corten	Vice President of Global Marketing	S.O.	S.O.	S.O.
Ms. Alicia Goodman	Chief Human Resources Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Cerus Corporation en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 7; Compensation : 5.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.